Thursday, 22 June 2017

Structural Heart Device to Prevent Blood Clots Entering the Blood Stream

Structural Heart Disease is a broad category of treatments for the patients with congenital & acquired heart diseases. These include structural anomalies and functional abnormalities. It was found that nearly 20% to 25%, which is roughly 60 million people in the U.S. suffer from SHD. 

What is SHD?

Structural heart disease (SHD) is a non-coronary hearts defect that does not affect the blood vessels. It is often found as a congenital heart defect (CHD). However, SHD can also be acquired during the later stages of life owing to wear & tear and other defects. The three major types of congenital heart diseases are coarctation of the aorta, Patent Foramen Oval (PFO), and Arterial Septal Defect (ASD). 

An Introduction

Recently, the U.S. Food & Drug Administration (FDA) approved an innovative technology called as “Watchman LAA”, developed by Boston Scientific. This closure technology is used as permanent implant delivery catheters for the treatment of strokes. It averts Left Atrial Appendage (LAA) blood clots from entering the bloodstream to prevent strokes. This device is made from self inflating Nitinol or nickel-titanium frame. 

Use of the Device

A medical professional inserts the delivery catheter into the leg vein of the patient. It reaches the right atrium, also known as upper right heart chamber of the heart through the bloodstream. The medical professional then makes a tiny incision in the wall between the two heart chambers. This hole helps the catheter reach the LAA.

Catheter then releases the device into the LAA. The device then opens like an umbrella and gets attached to appendage. In around 45 days, a thin layer of tissue grows over the implant. This layer prevents blood clot(s) from entering the bloodstream. This innovative device can be a boon for the patients of Atrial Fibrillation (AFib). 

Market Insights

The global structural heart devices market can reach USD 9.1 billion by 2025; according to a new research by Grand View Research, Inc. The market is anticipated to grow at around 9.15% CAGR over the forecast period (2014 to 2025). High awareness, rigid screening, easy access to treatments, and strong governmental support are some of the key market drivers. 

Market Rivals

Prominent players operating in the worldwide market for structural heart devices are Abbott Laboratories, Boston Scientific Corporation, Medtronic, and St. Jude Medical. Most companies often adopt mergers & acquisition and innovations to strengthen their product portfolio.

In-Depth research report on structural heart devices market:

No comments: